Abbott Laboratories $ABT Shares Sold by Bank of New York Mellon Corp

Bank of New York Mellon Corp trimmed its position in Abbott Laboratories (NYSE:ABT) by 0.5% in the third quarter, Holdings Channel.com reports. The fund owned 12,678,513 shares of the healthcare product maker’s stock after selling 60,159 shares during the period. Bank of New York Mellon Corp’s holdings in Abbott Laboratories were worth $1,698,160,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. Norges Bank acquired a new stake in Abbott Laboratories during the second quarter worth about $3,026,180,000. Laurel Wealth Advisors LLC boosted its position in Abbott Laboratories by 13,347.0% during the 2nd quarter. Laurel Wealth Advisors LLC now owns 6,056,934 shares of the healthcare product maker’s stock valued at $823,804,000 after purchasing an additional 6,011,891 shares during the period. Vanguard Group Inc. grew its stake in Abbott Laboratories by 1.8% during the 2nd quarter. Vanguard Group Inc. now owns 172,800,851 shares of the healthcare product maker’s stock worth $23,502,644,000 after buying an additional 2,977,715 shares during the last quarter. First Trust Advisors LP lifted its stake in Abbott Laboratories by 180.7% in the second quarter. First Trust Advisors LP now owns 3,063,443 shares of the healthcare product maker’s stock valued at $416,659,000 after buying an additional 1,972,097 shares during the last quarter. Finally, TD Asset Management Inc boosted its holdings in shares of Abbott Laboratories by 98.6% during the second quarter. TD Asset Management Inc now owns 3,467,896 shares of the healthcare product maker’s stock valued at $471,669,000 after acquiring an additional 1,721,523 shares during the period. 75.18% of the stock is currently owned by institutional investors.

Abbott Laboratories Stock Performance

ABT opened at $108.22 on Wednesday. The business has a fifty day simple moving average of $123.90 and a 200-day simple moving average of $127.95. The firm has a market cap of $188.18 billion, a PE ratio of 29.09, a P/E/G ratio of 1.73 and a beta of 0.72. Abbott Laboratories has a fifty-two week low of $105.78 and a fifty-two week high of $141.23. The company has a quick ratio of 1.24, a current ratio of 1.70 and a debt-to-equity ratio of 0.23.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, meeting analysts’ consensus estimates of $1.50. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.94%. The company had revenue of $11.46 billion during the quarter, compared to analyst estimates of $11.80 billion. During the same period in the prior year, the firm earned $1.34 earnings per share. The business’s quarterly revenue was up 4.4% on a year-over-year basis. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. As a group, equities analysts predict that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, February 13th. Stockholders of record on Thursday, January 15th will be issued a dividend of $0.63 per share. This is a positive change from Abbott Laboratories’s previous quarterly dividend of $0.59. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date is Thursday, January 15th. Abbott Laboratories’s dividend payout ratio is presently 67.74%.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the stock. Evercore ISI reduced their target price on shares of Abbott Laboratories from $144.00 to $138.00 and set an “outperform” rating for the company in a research note on Friday, January 23rd. Daiwa Capital Markets increased their price objective on Abbott Laboratories from $134.00 to $136.00 and gave the stock an “outperform” rating in a report on Tuesday, October 21st. Sanford C. Bernstein cut their target price on Abbott Laboratories from $154.00 to $125.00 and set an “outperform” rating on the stock in a research note on Friday, January 23rd. The Goldman Sachs Group decreased their price target on Abbott Laboratories from $152.00 to $140.00 and set a “buy” rating for the company in a research note on Friday, January 23rd. Finally, Piper Sandler reduced their price objective on shares of Abbott Laboratories from $150.00 to $135.00 and set an “overweight” rating for the company in a report on Friday, January 23rd. One research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, Abbott Laboratories presently has an average rating of “Moderate Buy” and a consensus target price of $140.79.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.